Cargando…
PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
BACKGROUND: Metastatic gastric cancer (MGC) patients with progression on first-line treatment still have poor outcomes on chemotherapy. The KEYNOTE-061 study demonstrated that pembrolizumab, a PD-1inhibitor, was not better than paclitaxel as second-line therapy for MGC. Herein, we explored the effic...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251434/ https://www.ncbi.nlm.nih.gov/pubmed/37304303 http://dx.doi.org/10.3389/fimmu.2023.1136437 |